RVMD: Revolution Medicines, Inc. Common Stock
Company identity verified 2026-11-21. Current quotes, news, filings and options load in the terminal; unavailable data is left unavailable.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites.
| Primary exchange (MIC) | XNAS |
|---|---|
| Listed since | 2020-02-13 |
| Market capitalization | $34.9 billion |
| Shares outstanding | 216,292,323 |
| Employees | 883 |
| Headquarters | REDWOOD CITY, CA, US |
| Website | www.revmed.com |
RVMD has traded between $160.22 and $169.51 in the current session, a range of $9.29. The latest price of $165.32 sits in the middle of that range (55% of the way from low to high). The volume-weighted average price is $163.25, and the stock is trading above it. Traders often use VWAP as a gauge of whether buyers or sellers have had the better average entry today.
| High | $169.51 |
|---|---|
| Low | $160.22 |
| Previous close | $159.43 |
| Volume | 4,742,046 |
| VWAP | $163.25 |
StockMarketLoop's Market Position model estimates how the shares traded between 2026-08-23 and 2026-11-21 were bought. Its estimate of the average cost basis is $186.37; at $165.32 the stock trades 11.3% below that level. About 5.1% of those shares are estimated to be held at a profit at the current price. A low figure means most recent buyers are underwater, so rallies can meet selling from holders trying to get back to break even. The densest nearby clusters of cost basis sit around $159.99 (support) and $191.88 (resistance). Roughly 70% of the estimated cost basis lies between $166.04 and $202.32, and 90% between $160.54 and $208.92.
This is a model estimate built from price and volume history, not a record of actual positions.
Quote figures come from StockMarketLoop's market data feed and may be delayed; the timestamp in the summary above shows when they were observed. Company details come from public reference data. The cost-basis section is a statistical model, not a forecast. Nothing here is investment advice; see our financial disclaimer and editorial policy.
Company identity verified 2026-11-21. Current quotes, news, filings and options load in the terminal; unavailable data is left unavailable.